Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 121Neoplasms, Plasma Cell 36Recurrence 7Immunoglobulin Light-chain Amyloidosis 5Renal Insufficiency 2Neoplasms 2Amyloidosis 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma 1Salivary Gland Neoplasms 1Renal Insufficiency, Chronic 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyneuropathies 1Plasmacytoma 1Pinealoma 1Pathologic Complete Response 1Paraproteinemias 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1

Interventions

Thalidomide 1Dexamethasone 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Thalidomide × Plasma cell × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡